By leveraging CR62 and a high-affinity TCR, we have conceptualized the TCR-based T-cell engager, CRPA1A2. Comprehensive preclinical assessments have been conducted to evaluate CRPA1A2's safety and efficacy.Results:CRPA1A2 is designed to specifically target the HLA-A*02:01-restricted MAGEA1 ...
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell cu...
Adoptive cell therapies involve infusing engineered immune cells into cancer patients to recognize and eliminate tumor cells. Adoptive cell therapy, as a form of living drug, has undergone explosive growth over the past decade. The recognition of tumor antigens by the T-cell receptor (TCR) is on...
overcome these limitations, recent improvements in T cell engineering have refocused on methods whereby the engineered receptors engage with and utilize endogenous TCRs rather than, as in the case with CAR-T therapies, bypassing the TCR complex. One such example includes theHLA-independentTCR (HIT)...
nM. A bispecific T-cell engager (BiTE) comprised of #21-3 and CD3 showed specific cytotoxicity towards cells bearing the SV2B80-88/HLA-A*24in vitroby crosslinking T-cells to the target cells. To the best of our knowledge, this is the first TCRm-Ab that targets the antigenic ...
NOVEL TECHNOLOGY Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and const...
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecificT cell engager antibody blinatumomab. J Hematol Oncol. 2015;8(1):111. Article PubMed PubMed Central Google Scholar Liao Z, Zhou L, Wang C, He Z, Wang X, Luo X, et al. ...
Mass spectrometry (MS) of HLA ligands from 8 hematologic and nonhematologic cancer cell lines identified a shared, non-immunogenic, HLA-A*02–restricted ligand (ALNEQIARL) derived from the kinetochore-associated NDC80 gene. CAR T cells directed against the ALNEQIARL:HLA-A*02 complex exhibited ...
Michaeli et al. “Expression Hierarchy of T Cell Epitopes From Melanoma Differentiation Antigens: Unexpected High Level Presentation of Tyrosinase-HLA-A2 Complexes Revealed b Peptide-Specific, MHC-Restricted, TCR-Like Antibodies”, The Journal of Immunology, XP007918402, 182(10): 6328-6341, May 15...
Abstract 3598: A new strategy for T cell therapy: T cells secreting TCR anti-CD3 bispecific T-cell engagerdoi:10.1158/1538-7445.AM2024-3598TCR-engineered T (TCR-T) cells and TCR-anti-CD3 bispecific T-cell engagers (TCEs) are potent TCR-based therapeutic agents with distinct advantages and...